The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynectics Regulatory News (SNX)

Share Price Information for Synectics (SNX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 190.00
Bid: 185.00
Ask: 195.00
Change: 0.00 (0.00%)
Spread: 10.00 (5.405%)
Open: 190.00
High: 190.00
Low: 190.00
Prev. Close: 190.00
SNX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directors / PDMRs' Interests in Shares

26 Mar 2024 07:00

RNS Number : 2436I
Synectics PLC
26 March 2024
 

 

 

 

 

 

 

 

 

26 March 2024

 

 

Synectics plc

("Synectics" or the "Company")

 

Directors / PDMRs' Interests in Shares

 

Synectics plc (AIM: SNX), a leader in advanced security and surveillance systems, announces that it has made an award of options ("Options") over, in aggregate, 140,000 ordinary shares of 20p each in the Company ("Ordinary Shares") under its existing Performance Share Plan ("PSP"), to certain Directors and Persons Discharging Managerial Responsibility ("PDMRs"), under its existing Performance Share Plan ("PSP"), as detailed below:

 

Name

Position

Status

Number of Options

Paul Webb

Chief Executive Officer

Executive Director

60,000

Amanda Larnder

Chief Financial Officer

Executive Director

40,000

David Aindow

Business Strategy Director

PDMR

20,000

David Gavin

Divisional Director

PDMR

20,000

 

Following these purchases, the above Directors' and PDMRs' interests in the Ordinary Shares are as follows:

 

Name

Number of Ordinary Shares held

Interest in Ordinary Shares in share schemes

Resultant total interest

% of issued share capital

Paul Webb

57,115

515,079

632,194

3.55

Amanda Larnder

4,326

164,000

168,326

0.95

David Aindow

2,000

80,000

82,000

0.46

David Gavin

0

80,782

80,782

0.45

 

Under the PSP, selected employees are entitled to exercise an option to receive a certain number of Ordinary Shares at any time after a three-year vesting period, exercisable at nil cost. The number of Ordinary Shares that are awarded at the end of the three-year period is dependent on the achievement of certain performance criteria and must be exercised within ten years of the date of award.

 

Vesting of the PSP award is measured according to the average of the Compound Annual Growth Rate ("CAGR") of the Total Shareholder Return Index and the CAGR of Adjusted Underlying Diluted Earnings Per Share. If this average is 20% or more, 100% of the award will vest. If this average is above 10% and below 20%, between 0% and 100% of the award will vest on a straight-line basis. If the average is 10% or less, 0% of the award will vest.

 

Any entitlement under the PSP will lapse on cessation of employment prior to the end of the three-year vesting period, unless cessation of employment is by reason of redundancy, ill health or death.

 

Should the performance criteria be met in full or in part for the Options, it is intended that the appropriate number of Options will be satisfied firstly from any unallocated Ordinary Shares already held within the Company's employee benefit trust with the balance to be satisfied from a new issue of Ordinary Shares.

 

Full details of the PSP were set out in the Company's Annual Report for the year ended 30 November 2023, copies of which are available on the Company's website, www.synecticsplc.com.

 

For further information, please contact:

 

Synectics plc

Paul Webb, Chief Executive Officer

Amanda Larnder, Chief Financial Officer

Claire Stewart, Company Secretary

email: info@synecticsplc.com

Tel: +44 (0) 114 280 2828

www.synecticsplc.com

 

 

Shore Capital

Tel: +44 (0) 20 7408 4090

Tom Griffiths / David Coaten / Rachel Goldstein

 

Vigo Consulting  

Jeremy Garcia / Fiona Hetherington / Aisling Fitzgerald 

synectics@vigoconsulting.com  

Tel: +44 (0) 20 7390 0230  

 

 

 

About Synectics plc

 

Synectics (AIM: SNX) is a leader in advanced security and surveillance systems that help protect people, property, communities, and assets around the world.

 

The Company's expertise is in providing solutions for specific markets where security and surveillance are critical to operations. These include gaming, oil and gas, public space, transport, and critical infrastructure.

 

Synectics has deep industry experience in these markets and works closely with customers to deliver solutions that are tailored to meet their needs. Technical excellence, combined with decades of experience and long-standing customer relationships, provides fundamental differentiation from mainstream suppliers and makes the Company a stand-out in its field.

 

Find out more at www.synecticsplc.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUNRRRSWUOURR
Date   Source Headline
24th Apr 202410:00 amRNSResult of AGM
24th Apr 20247:00 amRNSAGM Statement
17th Apr 20247:00 amRNSContract win with a major UK utility provider
9th Apr 20247:00 amRNSBoard Appointment and Grant of Options
3rd Apr 20247:00 amRNSDirector/PDMR Dealings
26th Mar 20247:00 amRNSDirectors / PDMRs' Interests in Shares
26th Mar 20247:00 amRNSDirector/PDMR Shareholding
19th Mar 20247:00 amRNSPosting of Annual Report & Accounts, Notice of AGM
27th Feb 20247:00 amRNSFinal Results
7th Feb 20247:00 amRNSNotice of Results and Investor Presentation
30th Jan 20247:00 amRNSContract Awards
19th Dec 20233:00 pmRNSHolding(s) in Company
11th Dec 20237:00 amRNSTrading Update
29th Nov 20237:00 amRNSContract Win
15th Nov 20237:00 amRNSInvestor Site Visit
23rd Oct 20237:00 amRNSDirectorate Changes
16th Oct 20237:00 amRNSLatest Release of Synectics’ Synergy Software
11th Oct 20237:00 amRNSDirector/PDMR Dealings
28th Sep 20237:00 amRNSAdditional Contract with West Midlands Police
11th Jul 20237:00 amRNSHalf-year Report
4th Jul 20237:00 amRNSContract Award
3rd Jul 20237:00 amRNSInvestor Presentation re interim results
19th Jun 20237:00 amRNSTrading Update and Notification of Results
11th May 20237:00 amRNSDirector dealings
2nd May 20237:00 amRNSNew Gaming Project in Asia
27th Apr 202311:51 amRNSResult of AGM
27th Apr 20237:00 amRNSAGM Statement
13th Apr 20237:00 amRNSContract Award
4th Apr 20238:09 amRNSDirector/PDMR Shareholding
23rd Mar 20237:00 amRNSPosting of Accounts and Notice of AGM
14th Mar 20237:00 amRNSPDMRs' Interests in Shares
22nd Feb 20237:00 amRNSFinal Results
17th Feb 20237:00 amRNSDirectorate Change
13th Feb 20237:00 amRNSNotice of Results
13th Dec 20227:00 amRNSTrading Update
1st Dec 20227:00 amRNSCompletion of sale of non-core Business
11th Nov 20227:00 amRNSSale of non-core Business
7th Nov 20227:00 amRNSDirectorate Change
24th Oct 20227:00 amRNSBoard Change and Update on Chairman Recruitment
4th Oct 20227:00 amRNSDirector/PDMR Shareholding
2nd Aug 20227:00 amRNSDirector’s and PDMRs' Interests in Share Schemes
12th Jul 20227:00 amRNSHalf-year Report
5th Jul 202212:00 pmRNSInvestor Presentation
5th Jul 20227:00 amRNSDirectorate Change
22nd Jun 20227:00 amRNSProposed Board Change
14th Jun 20227:00 amRNSTrading Update
1st Jun 20227:00 amRNSDirectorate Change
12th May 20228:12 amRNSDirector/PDMR Shareholding
11th May 20227:00 amRNSAmendment to Performance Share Plan
10th May 20227:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.